We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+0.65%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$73.9B
AUM Growth
-$2.32B
(-3%)
Cap. Flow
-$2.03B
Cap. Flow
% of AUM
-2.75%
Top 10 Holdings %
Top 10 Hldgs %
22.54%
Holding
3,088
New
92
Increased
1,359
Reduced
1,564
Closed
46
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$60.7M |
| 2 |
Analog Devices
ADI
|
+$46.1M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$37.3M |
| 4 |
Match Group
MTCH
|
+$28.2M |
| 5 |
GXO Logistics
GXO
|
+$19.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$89.3M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$78.9M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$77.4M |
| 4 |
Apple
AAPL
|
+$77M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$70.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.91% |
| 2 | Financials | 14.2% |
| 3 | Healthcare | 13.07% |
| 4 | Consumer Discretionary | 12.09% |
| 5 | Communication Services | 9.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1826
Caleres
CAL
$487M
| $2.31M | ﹤0.01% |
103,920
-14,160
| -12% | -$341K |
|
1827
Certara
CERT
$1.25B
| $2.31M | ﹤0.01% |
69,693
+38,304
| +122% | +$1.16M |
|
1828
Cohen & Steers
CNS
$4.3B
| $2.3M | ﹤0.01% |
27,421
-23,173
| -46% | -$1.96M |
|
|
ATSG
1829
DELISTED
Air Transport Services Group
ATSG
| $2.29M | ﹤0.01% |
88,823
+2,274
| +3% | +$57.4K |
|
|
APLS
1830
DELISTED
Apellis Pharmaceuticals
APLS
| $2.29M | ﹤0.01% |
69,395
+2,526
| +4% | +$142K |
|
1831
Outset Medical
OM
$90.8M
| $2.29M | ﹤0.01% |
3,083
+132
| +4% | +$89.9K |
|
1832
Arcus Biosciences
RCUS
$3.64B
| $2.28M | ﹤0.01% |
65,503
-25
| -0% | -$778 |
|
1833
Wabash National
WNC
$527M
| $2.28M | ﹤0.01% |
150,945
-24,150
| -14% | -$356K |
|
1834
Inovio Pharmaceuticals
INO
$69M
| $2.28M | ﹤0.01% |
26,564
+559
| +2% | +$56.1K |
|
1835
OraSure Technologies
OSUR
$279M
| $2.28M | ﹤0.01% |
201,734
-27,288
| -12% | -$300K |
|
|
KREF
1836
KKR Real Estate Finance Trust
KREF
$499M
| $2.28M | ﹤0.01% |
108,072
+6,484
| +6% | +$138K |
|
|
SRNE
1837
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $2.28M | ﹤0.01% |
298,752
+7,335
| +3% | +$62.2K |
|
|
NFBK
1838
DELISTED
Northfield Bancorp
NFBK
| $2.27M | ﹤0.01% |
132,225
-19,977
| -13% | -$329K |
|
1839
Winmark
WINA
$1.32B
| $2.27M | ﹤0.01% |
10,552
+3,328
| +46% | +$685K |
|
|
EVRI
1840
DELISTED
Everi Holdings
EVRI
| $2.27M | ﹤0.01% |
93,783
+3,288
| +4% | +$75.1K |
|
1841
Opko Health
OPK
$1.02B
| $2.27M | ﹤0.01% |
620,856
+18,201
| +3% | +$67.7K |
|
|
EFC
1842
Ellington Financial
EFC
$1.71B
| $2.26M | ﹤0.01% |
123,791
-9,951
| -7% | -$183K |
|
1843
Copa Holdings
CPA
$5.8B
| $2.26M | ﹤0.01% |
27,794
-2,195
| -7% | -$164K |
|
1844
CBIZ
CBZ
$2.96B
| $2.26M | ﹤0.01% |
69,857
+1,579
| +2% | +$51.4K |
|
1845
Atara Biotherapeutics
ATRA
$76.1M
| $2.26M | ﹤0.01% |
5,041
-40
| -0.8% | -$14.3K |
|
1846
SiriusPoint
SPNT
$2.68B
| $2.25M | ﹤0.01% |
243,261
-12,885
| -5% | -$124K |
|
|
CCRN
1847
DELISTED
Cross Country Healthcare
CCRN
| $2.25M | ﹤0.01% |
106,015
-12,859
| -11% | -$241K |
|
1848
Empire State Realty Trust
ESRT
$836M
| $2.25M | ﹤0.01% |
224,482
+5,716
| +3% | +$61.7K |
|
|
RC
1849
Ready Capital
RC
$308M
| $2.25M | ﹤0.01% |
155,790
-22,827
| -13% | -$346K |
|
1850
PJT Partners
PJT
$4.38B
| $2.24M | ﹤0.01% |
28,336
+919
| +3% | +$70.4K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2021 Portfolio in Review
As of Q3 2021, RhumbLine Advisers held 3,088 positions worth $73.9B, down 3% from $76.2B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Trading was light in Q3 2021: portfolio turnover was 4.5%. RhumbLine Advisers opened 92 new positions and exited 46, leaving the 3,088-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 23% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q3 2021 buy was GXO Logistics: 250,722 shares worth $19.7M.
- RhumbLine Advisers added most to Moderna in Q3 2021, an estimated $60.7M increase.
- RhumbLine Advisers's biggest Q3 2021 reduction was Microsoft, cutting an estimated $89.3M.
- RhumbLine Advisers fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $77.4M.
- RhumbLine Advisers's ten largest holdings make up 23% of its $73.9B portfolio in Q3 2021.
- RhumbLine Advisers opened 92 new positions and closed 46 in Q3 2021.
- RhumbLine Advisers's portfolio value fell 3% quarter-over-quarter to $73.9B.
Based on RhumbLine Advisers's 13F filing for Q3 2021, filed 12 Nov 2021.